Tresiba Cost in Maryland 2026: Prices, Coverage, and Savings Options

What Does Tresiba Actually Cost in Maryland?

Tresiba's Novo Nordisk list price sits at $510 per month in 2026, but almost no one pays that figure. The average cash-pay price at Maryland retail pharmacies is approximately $35 per month after applying available discount programs. The gap between list price and actual out-of-pocket cost is driven by manufacturer savings cards, pharmacy benefit manager contracts, and Medicaid coverage.

Insulin pricing in the United States remains complex because the list price (sometimes called the wholesale acquisition cost) rarely reflects what patients pay at the counter. A 2021 analysis published in JAMA Internal Medicine found that out-of-pocket insulin costs vary enormously by insurance status and pharmacy benefit design, with uninsured patients most exposed to list-price risk (1). Maryland residents who are uninsured or have high-deductible plans are therefore most at risk of paying close to the $510 figure without intervention.

The Novo Nordisk Patient Assistance Program and the Novo Nordisk savings card are the two fastest ways to close that gap. Eligible commercially insured Maryland patients can pay as little as $35 per month through the savings card program (2). Patients below certain income thresholds may qualify for free Tresiba through the Novo Nordisk Patient Assistance Program, which ships directly to the prescribing clinician's office or to the patient.

Maryland also enacted the Maryland Prescription Drug Affordability Board (PDAB) under SB 669 (2019), which has authority to set upper payment limits on high-cost drugs for state-regulated health plans. Tresiba has not yet had an upper payment limit imposed, but the PDAB's oversight framework gives Maryland patients more structural protection than most states provide.

How Maryland Medicaid Covers Tresiba

Maryland Medicaid (HealthChoice) covers Tresiba for both type 1 and type 2 diabetes, but requires prior authorization (PA) before the claim will process. The PA requirement is not unusual: most state Medicaid programs apply PA to basal insulin analogs to confirm clinical appropriateness and to steer toward lower-cost alternatives first (3).

The clinical case for Tresiba in Medicaid patients is strong. The DEVOTE trial (N=7,637) compared insulin degludec to insulin glargine U100 in adults with type 2 diabetes at high cardiovascular risk. Degludec produced significantly fewer severe hypoglycemic episodes: 4.9 vs. 6.6 events per 100 patient-years of exposure, a 27% lower rate (P<0.001), while achieving cardiovascular non-inferiority (4). Because severe hypoglycemia carries real downstream costs including emergency department visits, a prescriber making the PA case for Tresiba can cite DEVOTE's hypoglycemia data directly.

To obtain PA for a Maryland Medicaid patient, the prescribing clinician typically needs to document:

• A diagnosis of type 1 or type 2 diabetes with A1c goals and current regimen
• Prior trial of or contraindication to lower-cost basal insulins (glargine, detemir)
• Clinical rationale for why insulin degludec is medically necessary (for example, recurrent nocturnal hypoglycemia documented in chart notes)

Maryland Medicaid MCOs (CareFirst BlueCross BlueShield HealthChoice, UnitedHealthcare Community Plan, and others) each have their own PA forms, but the clinical documentation requirements are substantially similar. The prescribing office typically hears back within 72 hours for standard PA or within 24 hours for urgent PA.

Which Private Insurance Plans in Maryland Cover Tresiba?

Most large commercial health plans operating in Maryland include Tresiba on formulary at tier 3 or tier 4, meaning co-pays range from $50 to $150 per month before the deductible is met and from $25 to $75 per month once the deductible is satisfied. Specific plans available through the Maryland Health Benefit Exchange (Maryland's ACA marketplace) vary by formulary year, so patients should use the exchange's drug search tool or call the plan's pharmacy benefits line directly.

Employer-sponsored plans in Maryland follow federal formulary rules more than state mandates, and Tresiba's tier placement depends on whether the PBM (typically CVS Caremark, Express Scripts, or OptumRx) has negotiated a net price from Novo Nordisk that justifies a preferred tier. A 2023 analysis in Health Affairs found that insulin products with higher rebates were more likely to receive preferred formulary placement, independent of clinical differentiation (5).

The American Diabetes Association's 2024 Standards of Care state: "For patients with recurrent hypoglycemia or significant glycemic variability, insulin degludec or insulin glargine U300 may be preferred over first-generation basal insulins." (6) This guideline language gives clinicians a reimbursement justification when appealing a tier exception or PA denial.

The Novo Nordisk Savings Card: How It Works in Maryland

The Novo Nordisk savings card (marketed under the My$99Insulin program and separate co-pay assistance programs) is the most direct way for commercially insured Maryland patients to reduce Tresiba costs. The program works as a secondary payer: the card covers the difference between the insurance co-pay and the program's cap. As of 2026, eligible patients pay no more than $35 per month for a 30-day supply (7). Income or insurance type restrictions apply; Medicare and Medicaid patients cannot use the commercial savings card under federal law.

For uninsured Maryland patients, Novo Nordisk's $99 per month insulin cap program (announced in March 2023) covers Tresiba, Levemir, and NovoLog, regardless of income. Patients purchase a 90-day supply for $99, approximately $33 per month, through participating retail pharmacies. This program does not require a savings card activation. Patients present a specific coupon available at NovoCare.com. A 2023 Health Affairs Brief noted that Novo Nordisk's voluntary price cap reduced average transaction prices for covered insulins by 65 to 80% for uninsured patients (8).

Maryland retail pharmacies with confirmed Tresiba stock in 2026 include major chains (CVS, Walgreens, Rite Aid, Giant Food Pharmacy) and regional independents. Prices vary across pharmacies even before discounts. GoodRx and NeedyMeds aggregate coupons that may further reduce costs at specific locations, though these coupons cannot be combined with insurance and may price below the Novo Nordisk savings card in some cases.

Is Compounded Insulin Degludec Legal in Maryland?

Compounded insulin degludec is available in Maryland through licensed 503A compounding pharmacies, and the cash cost is effectively $0 per month in certain telehealth or clinic settings that absorb the compounding cost (9). The legal framework requires explanation.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound drugs for individual patients based on a valid prescription. Compounded drugs are not FDA-approved, meaning the FDA has not reviewed the specific compound for safety, efficacy, or manufacturing quality. Maryland's Board of Pharmacy permits 503A compounding and enforces state-level Good Compounding Practices standards.

Insulin degludec is not on the FDA's Demonstrably Difficult to Compound list, so 503A pharmacies may compound it legally provided:

• A licensed practitioner issues a patient-specific prescription
• The compounding is not done in advance of receiving valid orders (bulk compounding restrictions apply)
• The pharmacy is licensed in Maryland or ships under an out-of-state registration

The FDA has stated in its compounding guidance that commercially available products should not typically be compounded unless there is a documented clinical reason (such as allergy to an excipient in the branded product or a strength not commercially available) (10). Maryland clinicians writing compounded insulin degludec prescriptions should document clinical rationale in the chart. A 2022 analysis in Diabetes Care found that compounded insulin use, while growing, carries meaningful risks from inconsistent potency if the compounding pharmacy lacks strong quality controls (11).

Can You Get a Tresiba Prescription via Telehealth in Maryland?

Telehealth prescribing of Tresiba is fully permitted in Maryland. Maryland law does not restrict the prescribing of insulin through telehealth platforms, and the DEA's temporary telehealth flexibilities (extended through 2025 and carried into 2026 rulemaking) apply to controlled substances, not to insulin (12). Insulin is not a scheduled substance.

Maryland's telehealth parity law (Health-General Article, §15-139) requires commercial insurers to reimburse telehealth visits at parity with in-person visits. This means patients with commercial insurance can establish care with an endocrinologist or primary care clinician via video, receive a Tresiba prescription, and have the visit covered at the same rate as an office visit (13).

HealthRX clinicians licensed in Maryland can prescribe Tresiba after a synchronous video or phone consultation that meets Maryland's standard of care for a new prescription. The prescriber must document a diabetes diagnosis, current A1c, and basal insulin selection rationale. Prescriptions are sent electronically to the patient's preferred Maryland pharmacy. For patients using the Novo Nordisk savings card, the prescription must go to a participating pharmacy.

A 2021 systematic review in Diabetes Technology and Therapeutics (N=14 studies, 3,200+ patients) found that telehealth-based diabetes management produced A1c reductions of 0.5 to 1.2 percentage points versus usual care over 6 to 12 months (14).

Comparing Tresiba to Other Basal Insulins Available in Maryland

Tresiba (insulin degludec) has a half-life of approximately 25 hours and produces a duration of action beyond 42 hours at steady state, longer than any other FDA-approved basal insulin (15). This pharmacokinetic profile translates into flatter day-to-day variability in glucose lowering compared to insulin glargine U100, a finding confirmed in the BEGIN series of phase 3 trials (16).

For Maryland patients trying to decide between Tresiba and glargine products (Lantus, Basaglar, Toujeo), cost is often the deciding factor:

• Basaglar (glargine biosimilar) has a list price approximately 15% below Lantus, and a GoodRx price near $25 to $45 per month in Maryland pharmacies.
• Toujeo (glargine U300) has a similar list price to Tresiba and similar PA requirements under Maryland Medicaid.
• Tresiba's clinical advantage in hypoglycemia risk, documented in DEVOTE, may justify the additional hurdle of PA for patients with type 2 diabetes and prior hypoglycemic events (17).

The FDA approved the Tresiba FlexTouch pen and Tresiba PenFill cartridge in September 2015 for adults with type 1 and type 2 diabetes (18). No FDA-approved biosimilar for insulin degludec exists as of January 2026, meaning patients cannot substitute a lower-cost biosimilar at the pharmacy counter the way they can with glargine products.

Maryland-Specific Insulin Affordability Programs

Maryland offers several state-level resources that interact with Tresiba access.

The Maryland Insulin Cost Reduction Act does not currently impose a per-unit co-pay cap on Tresiba because Tresiba is not a biosimilar or generic insulin under Maryland's current statutory definition. However, SB 372 (2023) extended co-pay protections to additional insulin categories in state-regulated plans, and follow-on legislation is expected to expand coverage in 2026.

The Maryland Department of Health's Pharmacy Assistance Program (MAP) provides subsidized prescription coverage for Maryland residents who do not qualify for Medicaid but have incomes at or below 200% of the federal poverty level. MAP's formulary includes basal insulins; Tresiba is listed as a covered drug with a $20 co-pay per fill (19). Enrollment takes approximately two weeks and requires proof of Maryland residency and income documentation.

Free clinics operating in Baltimore, Rockville, Silver Spring, and Frederick have pharmacy dispensing agreements with Novo Nordisk that allow direct dispensing of Tresiba at no cost to qualifying patients. The Maryland Association of Free Clinics maintains a directory of participating sites (20).

Dose, Administration, and Storage: What Maryland Patients Need to Know

Tresiba is dosed once daily at any time of day, with the flexibility to shift the injection time by up to 8 hours without dose adjustment. This flexibility, confirmed in the BEGIN FLEX trial (21), is clinically meaningful for patients with irregular schedules.

The standard starting dose for insulin-naive type 2 diabetes patients is 10 units subcutaneously once daily, titrated every 3 to 4 days based on fasting glucose targets. Type 1 patients transitioning from another basal insulin should start unit-for-unit and adjust (22).

Tresiba should be stored in a refrigerator (2 to 8 degrees Celsius) before first use. After first use, the FlexTouch pen can be kept at room temperature (below 30 degrees Celsius) for up to 56 days. Do not freeze. Maryland's hot summers mean patients traveling or commuting should use an insulated insulin case to keep the pen below 30 degrees (23).

When to Contact a Maryland Endocrinologist About Switching to Tresiba

Switching basal insulins is not a decision to make without clinical oversight. Four clinical scenarios where a Maryland endocrinologist or primary care clinician should consider a Tresiba switch:

First, if a patient on glargine or detemir has documented nocturnal hypoglycemia occurring two or more times per month, the DEVOTE trial's 27% reduction in severe hypoglycemia rate gives evidence-based support for a switch (24).

Second, patients with highly variable schedules who cannot inject at the same time each day benefit from Tresiba's pharmacokinetic flexibility, specifically the 8-hour injection window (25).

Third, patients on very high basal insulin doses (greater than 80 units per day) may benefit from Tresiba's concentrated form (U200 FlexTouch), which delivers up to 160 units in a single 80-unit-dial injection.

Fourth, patients who have experienced recurrent emergency department visits for hypoglycemia generate healthcare costs that may justify insurer approval of Tresiba even when a PA is initially denied. Chart documentation of prior ED visits is a strong basis for appeal.

The American Association of Clinical Endocrinology (AACE) 2023 Comprehensive Type 2 Diabetes Management Algorithm states: "Second-generation basal insulins (degludec, glargine U300) are preferred when hypoglycemia risk is a primary concern." (26)